Contribute Try STAT+ Today

Earlier this month, 44 states filed a sweeping lawsuit that accused 20 generic drug makers, including large players such as Teva Pharmaceutical, and 15 current and former executives of a widespread price-fixing conspiracy. This was the second such lawsuit over the past three years that alleged schemes in which one company would decide to raise prices on a particular medicine and others would follow suit. The 524-page lawsuit also detailed how companies would agree to divide a market, rather than compete by lowering prices. In some instances, the coordinated price increases were over 1,000%. The lawsuits come amid a national debate over rising drug costs.

We spoke with Joseph Nielsen, an assistant attorney general in Connecticut, which has taken the lead on these cases, about some of the details and what to expect next. This is an edited version of our conversation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.